Genetics
Genetics
批准号:
7929675
负责人:
YOSEF REFAELI
金额:
$15.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AN-1Antigen ReceptorsAntigensApoptosis RegulatorB-LymphocytesCell LineCellsDevelopmentEmerging TechnologiesFamilyGene ExpressionGenerationsGenesGeneticGoalsHematopoieticHematopoietic stem cellsHomeostasisLymphocyteLymphoid CellMediatingMolecularMouse StrainsMusNF-kappa BNaturePTEN genePathway interactionsProcessProductionProtein FamilyReceptors, Antigen, B-CellResearch PersonnelResourcesRoleSignal TransductionSpecificityTechnologyTrainingTraining SupportTransgenic MiceViralViral Vectorautoreactive B cellbasecDNA Expressiondesigngain of functiongenetic manipulationimprovedinterestkillingsloss of functionmembernew technologyoverexpressionpluripotencyprogramssmall hairpin RNAtoolvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This core aims to provide access, support and training for three new and emerging technologies for the
projects described in this program. In addition, the core seeks to continue to develop and improve of the
application of the three technologies described for the specific needs of the projects described in this
program. The specific technologies include: a) the development of a comprehensive and technically
advanced resource for the design, generation and production of viral-based shRNA vectors as well as
retroviral approaches to manipulate ectopic gene expression in primary cells and cell lines of interest, b) the
use of genetically modified mice for the efficient immortalization of autoreactive B-cells, and c) the use of
novel technologies to conditionally immortalize long term hematopoietic stem cells in order to generate cell
lines from transgenic mice of interest for these projects. The three specific aims of this core are:
To develop a suite of viral vectors that will be useful for genetic manipulation of primary lymphoid cells. The
use of viral mediated delivery of shRNA will be the primary tool for loss-of-function studies whereas the use
of retroviral driven cDNA expression will be the primary means of gain-of-function studies in mice.
1. To use mice that overexpress MYC in an inducible, and B-cell specific manner to immortalize
autoreactive B-cells (AN-1 cells). This approach will be important for Dr. Cambier's project and their
attempts to determine the nature and specificity of the B-cell antigen receptors on normal AN1/T3
cells.
2. To define the hematopoietic pluripotency of conditionally immortalized long-term hematopoietic stem
cell clones.
The genetic pathways we will focus on will be of broad interest and application to the other projects in this
program, and we will train and assist those investigators in this process as needed. This core will be
important in allowing the different projects described in this program to define the molecular basis by which
antigen receptor derived signals are able to regulate lymphocyte tolerance, homeostasis and survival.
Depending on the specific circumstances, the antigen receptor can anergize, tolerize or kill lymphoid cells
with the ultimate goal of generating an innocuous but useful repertoire. The projects described in this project
will focus initially on the role of members of the Bcl-2 family in these functions of the antigen receptors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The consequences of loricrin deficiency on epidermal barrier function
-
批准号:8871513
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2011
-
负责人:YOSEF REFAELI
-
依托单位:
The consequences of loricrin deficiency on epidermal barrier function
-
批准号:8488416
-
项目类别:
-
资助金额:$31.34万
-
财政年份:2011
-
负责人:YOSEF REFAELI
-
依托单位:
The consequences of loricrin deficiency on epidermal barrier function
-
批准号:8706798
-
项目类别:
-
资助金额:$32.33万
-
财政年份:2011
-
负责人:YOSEF REFAELI
-
依托单位:
The consequences of loricrin deficiency on epidermal barrier function
-
批准号:8326630
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2011
-
负责人:YOSEF REFAELI
-
依托单位:
Genetics
-
批准号:8311796
-
项目类别:
-
资助金额:$15.68万
-
财政年份:2011
-
负责人:YOSEF REFAELI
-
依托单位:
The consequences of loricrin deficiency on epidermal barrier function
-
批准号:8189285
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2011
-
负责人:YOSEF REFAELI
-
依托单位:
Large-scale generation of human red blood cells for transfusion therapy
-
批准号:7994247
-
项目类别:
-
资助金额:$15.14万
-
财政年份:2010
-
负责人:YOSEF REFAELI
-
依托单位:
Molecular based strategies to generate protective immune responses to HIV-1
-
批准号:7927825
-
项目类别:
-
资助金额:$17.18万
-
财政年份:2010
-
负责人:YOSEF REFAELI
-
依托单位:
Genetics
-
批准号:7663285
-
项目类别:
-
资助金额:$15.36万
-
财政年份:2008
-
负责人:YOSEF REFAELI
-
依托单位:
Rapid Generation of Human Therapuetic Antibodies Against Influenza
-
批准号:7480790
-
项目类别:
-
资助金额:$18.07万
-
财政年份:2008
-
负责人:YOSEF REFAELI
-
依托单位:
Generating HIV resistant cells from conditionally transformed HSC cell lines
-
批准号:7419068
-
项目类别:
-
资助金额:$16.12万
-
财政年份:2008
-
负责人:YOSEF REFAELI
-
依托单位:
Generation of HIV resistant cells from protein transduced hematopoetic stem cell
-
批准号:8111916
-
项目类别:
-
资助金额:$75.92万
-
财政年份:2008
-
负责人:YOSEF REFAELI
-
依托单位:
Generation of HIV resistant cells from protein transduced hematopoetic stem cell
-
批准号:8012229
-
项目类别:
-
资助金额:$66.06万
-
财政年份:2008
-
负责人:YOSEF REFAELI
-
依托单位:
Genetics
-
批准号:7188254
-
项目类别:
-
资助金额:$15.29万
-
财政年份:2007
-
负责人:YOSEF REFAELI
-
依托单位:
MYC-induced breach of B-cell anergy in AIDS-related NHLs
-
批准号:7417456
-
项目类别:
-
资助金额:$24.2万
-
财政年份:2006
-
负责人:YOSEF REFAELI
-
依托单位:
MYC-induced breach of B-cell anergy in AIDS-related NHLs
-
批准号:7799252
-
项目类别:
-
资助金额:$35.99万
-
财政年份:2006
-
负责人:YOSEF REFAELI
-
依托单位:
MYC-induced breach of B-cell anergy in AIDS-related NHLs
-
批准号:7247943
-
项目类别:
-
资助金额:$24.2万
-
财政年份:2006
-
负责人:YOSEF REFAELI
-
依托单位:
MYC-induced breach of B-cell anergy in AIDS-related NHLs
-
批准号:7119877
-
项目类别:
-
资助金额:$24.92万
-
财政年份:2006
-
负责人:YOSEF REFAELI
-
依托单位:
MYC-induced breach of B-cell anergy in AIDS-related NHLs
-
批准号:7931750
-
项目类别:
-
资助金额:$36.11万
-
财政年份:2006
-
负责人:YOSEF REFAELI
-
依托单位:
Genetics
-
批准号:8134393
-
项目类别:
-
资助金额:$16.12万
-
财政年份:--
-
负责人:YOSEF REFAELI
-
依托单位:
海外基金